Development of Harmonized Indicators and Estimation Procedures for Forests with Protective Functions against Natural Hazards in the Alpine Space

The present study was developed in the context of Regulation (EC) 2152/2003 on the monitoring of forest and environmental interactions, the so-called "Forest Focus" Regulation. The specific objective of this study was to explore the possible contribution of the national forest inventories (NFIs) to assess protective functions of for-ests in the alpine space. Key components of protective functions could be determined with the help of on-going national and international studies and processes. In order to grant consistency, definitions of forest area, dam-age potential and hazard potential had to be harmonised. Based on those, a strategy for monitoring and report-ing aspects of protective functions of mountain forests in the alpine space was proposed. Estimation procedures based on existing NFI data and field assessments and their integration in different remote sensing techniques were tested for harmonised monitoring. Final results are presented in this report.JRC.DDG.H.7-Land management and natural hazard

Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs)

Abstract not available

Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs)

Abstract not available

PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

BACKGROUNDNo systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.METHODSWe report the results of the phase 1 study of cemiplimab for expansion cohorts of patients with locally advanced or metastatic cutaneous squamous-cell carcinoma, as well as the results of the pivotal phase 2 study for a cohort of patients with metastatic disease (metastatic-disease cohort). In both studies, the patients received an intravenous dose of cemiplimab (3 mg per kilogram of body weight) every 2 weeks and were assessed for a response every 8 weeks. In the phase 2 study, the primary end point was the response rate, as assessed by independent central review.RESULTSIn the expansion cohorts of the phase 1 study, a response to cemiplimab was observed in 13 of 26 patients (50%; 95% confidence interval [CI], 30 to 70). In the metastatic-disease cohort of the phase 2 study, a response was observed in 28 of 59 patients (47%; 95% CI, 34 to 61). The median follow-up was 7.9 months in the metastatic-disease cohort of the phase 2 study. Among the 28 patients who had a response, the duration of response exceeded 6 months in 57%, and 82% continued to have a response and to receive cemiplimab at the time of data cutoff. Adverse events that occurred in at least 15% of the patients in the metastatic-disease cohort of the phase 2 study were diarrhea, fatigue, nausea, constipation, and rash; 7% of the patients discontinued treatment because of an adverse event.CONCLUSIONSAmong patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors

[Sheet No 4728] ; Mühlhausen ; geological map

Geologische Karte 1: 25 000 mit Erläuterungen. Digitalisat des FID GEO (Fachinformationsdienst Geowissenschaften der festen Erde), erstellt durch das GDZ (Göttinger Digitalisierungszentrum), Karte aus dem Bestand der SUB Göttingen.mapDFG, SUB Göttinge